Kenji Terashi
About
In The Last Decade
Kenji Terashi
21 papers receiving 377 citations
Peers
Comparison fields: 5 of 62
- Oncology 254
- Molecular Biology 185
- Pulmonary and Respiratory Medicine 55
- Pediatrics, Perinatology and Child Health 47
- Organic Chemistry 44
Countries citing papers authored by Kenji Terashi
This map shows the geographic impact of Kenji Terashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Terashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Terashi more than expected).
Fields of papers citing papers by Kenji Terashi
This network shows the impact of papers produced by Kenji Terashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Terashi. The network helps show where Kenji Terashi may publish in the future.
Co-authorship network of co-authors of Kenji Terashi
This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Terashi. A scholar is included among the top collaborators of Kenji Terashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Terashi. Kenji Terashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. | 20 |
| 2 | 13 | |
| 3 | 10 | |
| 4 | 27 | |
| 5 | 56 | |
| 6 | 33 | |
| 7 | 3 | |
| 8 | Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. | 39 |
| 9 | Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells. | 12 |
| 10 | Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells. | 13 |
| 11 | 22 | |
| 12 | Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy. | 17 |
| 13 | 29 | |
| 14 | 23 | |
| 15 | [Primary pulmonary non-Hodgkin's lymphoma in a patient with dermatomyositis]. | 1 |
| 16 | [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma]. | 2 |
| 17 | 6 | |
| 18 | 1 | |
| 19 | 8 | |
| 20 | 38 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.